N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use

US7858647B2 · kind B2 · utility

Assignee

• Sanofi-Aventis · FR

Inventors

• Stefanie Keil · Frankfurt am Main, DE
• Hans Matter · Langenselbold, DE
• Karl Schoenafinger · Alzenau, DE
• Matthias Urmann · Eschborn, DE
• Maike Glien · Frankfurt am Main, DE
• Wolfgang Wendler · Bad Camberg, DE
• Hans-Ludwig Schaefer · Frankfurt am Main, DE
• Eugen Falk · Frankfurt am Main, DE

Key dates

• Filing date: Apr 4, 2008
• Grant date: Dec 28, 2010
• Expiry date: Jul 10, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D285/135
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below,And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.